AstraZeneca Plc - Company Profile
Powered by 
All the data and insights you need on AstraZeneca Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date AstraZeneca Plc Strategy Report
- Understand AstraZeneca Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreView up-to-date information on AstraZeneca Plc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4058060A1 | Application | TYP-I-INTERFERON-HEMMUNG BEI SYSTEMISCHEM LUPUS ERYTHEMATODES | A61K2039/505; A61K2039/545; A61K47/183; A61K47/22; A61K47/26; A61P37/00; C07K16/2803; C07K16/2866; C07K2317/21; C07K2317/24; C07K2317/76 | September 21, 2022 |
| WO2022192139A1 | Application | AURORA KINASE B INHIBITORS FOR USE FOR TREATING CANCER | A61K31/00; A61K31/506; A61K31/517; A61K45/06; A61P35/00; C12Q1/485; C12Y207/11001; G01N2440/14; G01N33/57484 | September 15, 2022 |
| AU2021213403A1 | Application | Anti-αvβ8 integrin antibodies for use in treating kidney disease | A61K2039/505; A61P13/12; C07K16/2839; C07K2317/24; C07K2317/76; C07K2317/92 | September 15, 2022 |
| EP4054582A1 | Application | THERAPEUTISCHE KOMBINATIONEN VON ACALABRUTINIB UND CAPIVASERTIB ZUR BEHANDLUNG VON B-ZELL-MALIGNITÄTEN | A61K2300/00; A61K31/4985; A61K31/519; A61P35/00 | September 14, 2022 |
| EP4055044A1 | Application | ANTI-IL-33-THERAPEUTIKUM ZUR BEHANDLUNG VON NIERENERKRANKUNGEN | A61K2039/505; A61P13/12; C07K16/244; C07K16/2803; C07K16/2863; C07K16/2866; C07K2317/76; C07K2317/92 | September 14, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer